Filing Flows › Comparisons › AIM vs SNTI
AIM ImmunoTech vs Senti Biosciences Holdings: AIM and SNTI compared
AIM ImmunoTech is the larger company: $26K of revenue in its latest quarter (Q2 2026) against $17K for Senti Biosciences Holdings (Q2 2026).
Where the money goes: AIM and SNTI
AIM ImmunoTech (AIM) · Q2 2026
AIM ImmunoTech, Q2 2026: revenue $26K (+4% year over year), net loss $3.8M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
Senti Biosciences Holdings (SNTI) · Q2 2026
Senti Biosciences Holdings, Q2 2026: revenue $17K, net loss $12.8M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
| AIM ImmunoTech (AIM) | Senti Biosciences Holdings (SNTI) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $26K | $17K |
| Revenue growth, Y/Y | +4% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$3.8M | −$12.8M |
| Operating cash flow | −$4.6M | −$14.2M |
Questions
Which is bigger, AIM ImmunoTech or Senti Biosciences Holdings?
AIM ImmunoTech is the larger company: $26K of revenue in its latest quarter (Q2 2026) against $17K for Senti Biosciences Holdings (Q2 2026).
More: AIM ImmunoTech earnings · how AIM ImmunoTech makes money · Senti Biosciences Holdings earnings · how Senti Biosciences Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 7, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.